The Men’s Safer Sex (MenSS) Trial: protocol for a pilot randomized controlled trial of an interactive digital intervention to increase condom use in men

Summary

Background

Sexually transmitted infections (STI) are a major public health problem. While condoms provide effective protection, there are many barriers to use. Face-to-face interventions to promote condom use show mixed results, and are costly and resource-intensive to deliver. Interactive digital interventions may provide a suitable alternative, giving self-directed, private access to personally tailored information and behaviour change activities. We have developed an interactive digital intervention (the MenSS website) which aims to increase condom use in heterosexual men in sexual health clinic settings.

Objective

To conduct a pilot trial to assess the feasibility of a full-scale randomized controlled trial of the MenSS intervention website to increase condom use in men attending sexual health clinics.

Design

Male sexual health clinic attendees aged 16 or over who have female sexual partners, have a history of recent unprotected sex or suspected STI and no history of hepatitis or HIV will be invited to participate. Participants (N = 166) will be enrolled using a tablet computer (iPad™) available in clinic waiting rooms. All trial procedures will be online, i.e. eligibility checks; study consent; trial registration; and self-reported data submission.

Participants will be randomly allocated by automated computer algorithm to receive either usual clinical care only or usual clinical care plus the MenSS safer sex website.

At baseline (prior to randomisation), participants will be asked to complete measures of condom use, self-reported STI diagnoses, and mediators of condom use (e.g. knowledge). These measures will be repeated 3, 6 and 9 months later, following-up by email and mobile phone. The primary outcome is condom use in the last 3 months, measured at the 3-month follow-up. At 12 months, participants will be asked to complete an online questionnaire assessing a full range of sexual health outcomes, and STI rates will be assessed by reviewing sexual health clinic medical records. The feasibility of a cost effectiveness analysis will also be assessed, to calculate incremental cost per STI prevented (Chlamydia or Gonorrhoea), comparing intervention participants with controls, from the NHS perspective.

This pilot trial will determine the optimal design for a full-scale phase III randomised controlled trial to test the effect of the MenSS website on condom use and STI.
1. Background

1.1. Men’s sexual health

Sexually transmitted infections (STI) are a major public health problem, with high social and economic costs. In 2012, there were around 450,000 diagnoses of STI in England – 5% more than in 2011 – with young people aged 16-24 accounting for a large proportion of diagnoses.

Condoms are effective for prevention of STI; however, there are many barriers to successful use, for example decrease in sensation, interruption of sex, incorrect size or fit, use of alcohol/recreational drugs, anxiety affecting sexual performance, and stigma associated with carrying condoms. The prevention of pregnancy is often a stronger motivation for condom use than prevention of STI. Condoms may be perceived as a barrier to intimacy and trust, and use is often lower in established relationships.

Since it is men who primarily experience many of the disadvantages of using male condoms (e.g. reduced pleasure), and have power to influence condom use for penetrative sex (since they wear condoms), prevention efforts are needed to target the obstacles to condom use that men face. While there are a variety of health promotion interventions aimed at improving sexual health outcomes for men who have sex with men (MSM), there are fewer interventions specifically for adult men who have sex with women (MSW), despite the fact that MSW report much less consistent condom use than MSM. Men are less likely than women to visit health professionals and generally have shorter clinic appointments, so may be less likely to be offered health promotional advice or risk reduction counselling in the context of routine appointments. Men may be reluctant to discuss their sexual health with health professionals, partners or friends. An online intervention therefore offers an alternative avenue to reach men.

1.2. Sexual health interventions

Guidance from the National Institute for Health and Care Excellence recommends that people at high risk of STI are offered one-to-one structured discussions to address risk-taking, and this is increasingly being offered as part of routine care in genito-urinary medicine (GUM) and other health care settings. Whilst interventions such as motivational interviewing can impact on sexual behaviour, in practice it is resource-intensive to train and support staff, and difficult to find time for structured discussions in busy clinical services. A potential alternative to such interventions is the use of interactive digital interventions (IDI).

We define IDI as ‘Computer-based programmes that provide information and one or more of decision support, behaviour-change support, or emotional support for health issues’. IDI require contributions from users to produce personally relevant tailored material and feedback. IDI are highly suitable for sexual health promotion because access can be private, anonymous and self-paced, which may be particularly important for men who may be reluctant to disclose a lack of knowledge or skill. Interventions can be targeted for specific groups (e.g. by age, gender or sexuality), and content can be tailored for individuals. IDI can be expensive to develop but offer the advantages of intervention fidelity and the potential to reach large audiences at relatively low dissemination costs.
IDI can improve sexual behaviour (including condom use)\textsuperscript{13,18} as well as increasing knowledge, self-efficacy and safer sex intention.\textsuperscript{13,19} More evidence is needed to establish effects on biological outcomes (STI) and cost-effectiveness. The MenSS (Men’s Safer Sex) website is an IDI which aims to increase condom use and reduce sexually transmitted infections in men attending sexual health clinics. The present pilot trial aims to determine the optimum parameters of a full-scale randomised controlled trial (RCT) to assess the efficacy of the MenSS website intervention.

2. Principal investigators

Chief investigator: Dr. Julia Bailey  
Trial manager: Dr. Rosie Webster  
Principal investigator:  
Barts Health NHS trust Dr. Claudia Estcourt, c.s.estcourt@qmul.ac.uk, Tel: 020 7882 2316

Homerton University Hospital NHS Foundation Trust  
Prof. Jane Anderson, janderson@nhs.net

City of Coventry Health Centre Integrated Sexual Health Services Department  
Dr. Belinda Stanley, Belinda.Stanley@covwarkpt.nhs.uk, Tel:02476 961597

3. Main centres

Department of Sexual Health  
Homerton Hospital  
Homerton Row  
London E9 6SR

Barts Sexual Health Centre  
Kenton and Lucas Wing  
St Bartholomew’s Hospital  
West Smithfield  
London EC1A 7BE

City of Coventry Health Centre Integrated Sexual Health Services Department  
3rd Floor  
Stoney Stanton Road,  
CV1 4FS
4. **Aim(s)**

To establish the feasibility and optimal design of a full-scale randomized controlled trial to test the effect on condom use and STI acquisition of the MenSS intervention website for men attending sexual health clinics:

- Conduct a pilot trial to optimise the parameters for a Phase III randomised controlled trial of usual clinical care plus the IDI compared to usual clinical care only, using the primary outcome of self-reported condom use at 3-month follow-up
- Optimise the data collection and analysis procedures for a health economic analysis for a future Phase III randomised controlled trial

5. **Methods**

5.1. **Design**

The pilot trial will be a phase II proof of concept randomised controlled trial to evaluate the effect of the MenSS IDI on increasing condom use in comparison with usual clinic care for men in sexual health clinics.

5.2. **Setting**

Participants will be recruited from three sexual health clinics: The Homerton Hospital Department of Sexual Health, St Bartholomew’s Sexual Health Centre, and City of Coventry Health Centre Integrated Sexual Health Services Department. These clinics serve a diverse range of patients in terms of age, socio-economic status and ethnicity.

5.3. **The Intervention:**

The MenSS website content and design was developed based on evidence from the sexual health literature and theories of behaviour change, qualitative interviews with men in sexual health clinics, and discussions with clinical and academic experts in sexual health and digital technologies. The development process was iterative, with a high level of user involvement. The intervention is designed to be delivered initially in clinic, to make use of the time when patients are waiting to be seen, but also providing (and encouraging) online access after patients have left the clinic.

The MenSS intervention consists of an interactive website. Whilst in clinic, users will be presented with a tailored package of website content which addresses individual men’s barriers to condom use. The site targets a number of influences on effective condom use, such as:

- Condom knowledge (e.g. about sizes and types of condoms)
- Condom use skills
- Difficulties in negotiating condom use
- Inaccurate beliefs about STI risk
- Social influences, such as perceived/expected partner response
- Sexual pleasure
- Being caught in the ‘heat of the moment’
- Alcohol and drug use

Whilst in clinic, users will be asked to select their own personal barriers to condom use. This task will produce a tailored package of information, offering solutions or counter-arguments to barriers (including interactive activities and quizzes, videos and case vignettes), which will be presented prominently on the homepage. Some content is presented to all users (e.g. training in condom use skills), and all content will be available via navigation tabs. Participants will be led through their tailored content package sequentially, and are asked to set goals to change their behaviour. If wanted, participants will receive emails to assess achievement of goals, and to encourage them to visit the intervention website again.

5.4. Procedure

Participant recruitment is designed to be self-directed, using a touch-screen tablet computer, which will be available in the clinic waiting room. Participants will be directed to the tablet computer via brief information leaflets and posters in the waiting room, or by clinic staff. The trial software is set-up to allow participants to be led through the steps of screening, consent, automatic randomisation, data collection, and intervention viewing, without assistance from clinic staff (see Figure 1). A member of the study team or the sexual health clinic research staff will be present if needed to assist and answer questions.
Figure 1. Trial software framework: online study information, consent, registration, data collection and randomisation
Online eligibility, consent, registration, randomization, data collection

The tablet computer in the clinic waiting room will present information about the trial and an invitation to participate. Potential participants will then be asked to complete a screening questionnaire to determine their eligibility for the trial. Those who are ineligible at this point will be informed of this, and thanked for their time. Those who are eligible will receive detailed information regarding the study. Participants will then be asked to give informed consent by agreeing to a number of statements (e.g. that they understand what is involved, that we may access their medical records and that they agree to take part). Participants will then be asked to give their contact details (email address and telephone number), in order to contact them for follow up assessments, to send them reminders to view the website, and to remind them that they are participating in the trial, and to send an electronic shopping voucher to recompense participants for their time. Participants will also be asked to create a password which will allow the allocation of a unique ID for each participant. The password will give the intervention group access to the intervention website, which will also enable collection of website usage data. The password will also be needed to access the follow-up questionnaires. Demographic and baseline sexual health data will then be collected (see ‘Measures’). At this point, the software programme will use a computer algorithm to allocate participants to either the intervention or control conditions. This allocation will be unalterable.

5.4.1. Follow-up data collection

At three, six, nine, and twelve months after their initial clinic visit, participants will receive an automated email asking them to complete a follow-up questionnaire (see ‘Outcome assessments’), by clicking on a web link to the online questionnaire. If they do not complete the questionnaire, they will receive 3 further email prompts, at one-week intervals, as well as 3 text messages to their mobile phone (again, including the web link) alongside the latter two emails. If participants still do not respond, the researcher will telephone participants a week after the final email, reminding them about the questionnaire and offering them the opportunity to complete it over the telephone. Information about STI diagnoses will be collected at all time-points via self-report, and at 12 months by recording diagnoses or suspected diagnoses over the last year recorded in the clinical notes at the sexual health clinics participants are recruited from.

5.5. Inclusion and exclusion criteria

5.5.1. Inclusion criteria:

Men aged 16 years and over (with no upper age limit); able to read English; with access to the Internet; and at high risk of future STI (i.e. two or more partners in the past year (male or female) and some non-condom use in the last 3 months; or symptoms of acute STI; or seeking treatment for an STI); and for whom at least half of their sexual partners are female.

5.5.2. Exclusion criteria:

HIV positive men and men with hepatitis B or C will be excluded, since patients with these diagnoses are likely to receive more intensive input in the course of routine clinical care.
We will exclude men who have had sexual experience only ever with males, more often with males but at least once with a female, or no sexual experience at all.\textsuperscript{21}

\textbf{5.6. Randomisation}

Once participants have been checked for eligibility, given informed consent, and submitted baseline data, they will be allocated by computer algorithm randomisation system to either the intervention or control group. The participant will be informed with an automated message on the tablet computer, and this allocation will be unalterable.

\textbf{5.7. Allocation concealment}

Allocation will be undertaken using a concealed automated computer-based algorithm, which will be immediate.

Participants allocated to the control condition will be notified that they have not been selected to view the intervention and told they will be contacted again in 3, 6, 9, and 12 months to gather follow-up data. Those allocated to the intervention condition will be directed to the intervention website where they will be presented with a tailored package of health promotion/behaviour change content. Website usage (page views) will be automatically recorded.

\textbf{5.8. Assessment}

\textbf{5.8.1. Development of the online measurement instrument}

We adapted the Sexunzipped online sexual health questionnaire\textsuperscript{22} to encompass comprehensive measurement of outcomes and mediators of condom use. We selected items for inclusion based on a literature search for established measures, and consultation with experts. We conducted interviews with men in sexual health clinics (\(N = 11\)) to gain feedback on successive versions of the outcome questionnaire. Interviews with men checked their understanding of questions, the clarity of questions, and content suitability for the selected measures of behavioural outcomes and mediators of those outcomes. Based on feedback we modified the structure and content of the outcome questionnaire.

Mediators of behaviour change (e.g. beliefs about pleasure, motivation, knowledge, self-efficacy), behavioural outcomes (including condom use, STI testing, communication with partner/s), and cumulative STI incidence (self-reported and from clinical notes) will be measured. Service use and Quality of Life will be measured for the cost-effectiveness analysis. The primary outcome will be self-reported condom use at 3 month follow-up.

\textbf{5.8.2. Measures}

In the light of evidence that measurement alone may prompt behaviour change,\textsuperscript{23} we will measure a limited number of outcomes (condom use and the main mediators, and self-reported STI diagnoses) at baseline; and will assess a full range of outcomes at 3, 6, 9, and 12 months (see Table 1). All assessments have a recall period of the previous 3 months, which is the time between follow-up assessments.
Table 1 Variables assessed at each time point

<table>
<thead>
<tr>
<th>Baseline measures</th>
<th>3, 6, 9, and 12 month follow-up assessments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic details (age, occupation, ethnicity)</td>
<td></td>
</tr>
<tr>
<td><em>Outcomes</em></td>
<td></td>
</tr>
<tr>
<td>Sexual partners</td>
<td>Sexual partners</td>
</tr>
<tr>
<td>Condom use – episodes and partners</td>
<td>Condom use – episodes and partners</td>
</tr>
<tr>
<td>Self-reported STI diagnoses</td>
<td>Self-reported STI diagnoses</td>
</tr>
<tr>
<td>Contraception use and pregnancy</td>
<td>Contraception use and pregnancy</td>
</tr>
<tr>
<td>Health-Related Quality of Life</td>
<td>Health-Related Quality of Life</td>
</tr>
<tr>
<td>Service use</td>
<td></td>
</tr>
<tr>
<td><em>Mediators of condom use</em></td>
<td></td>
</tr>
<tr>
<td>Motivation to use condoms</td>
<td>Motivation to use condoms</td>
</tr>
<tr>
<td>Intentions to use condoms</td>
<td>Intentions to use condoms</td>
</tr>
<tr>
<td>Beliefs about pleasure</td>
<td>Beliefs about pleasure</td>
</tr>
<tr>
<td>Non-condom use due to intoxication</td>
<td>Non-condom use due to intoxication</td>
</tr>
<tr>
<td>Evaluation of condoms</td>
<td></td>
</tr>
<tr>
<td>Communication</td>
<td></td>
</tr>
<tr>
<td>Identity</td>
<td></td>
</tr>
<tr>
<td>Self-efficacy</td>
<td></td>
</tr>
<tr>
<td>Condom problems</td>
<td></td>
</tr>
<tr>
<td>Knowledge</td>
<td></td>
</tr>
</tbody>
</table>
5.8.3. Outcome measures

The online outcome measurement instrument is detailed in full in Appendix 1.

Demographics

Questions at baseline will collect demographic information including age, employment status and ethnicity.

Condom use

The objective of the study is to promote condom use with female partners, so the primary outcome is the number of episodes of unprotected vaginal sex (without a condom) over the previous 3 months, assessed at the 3 month follow-up. We expect the majority of change in behaviour to occur shortly after recruitment, as we expect users will be most likely to engage with the intervention during the clinic visit.

Sexual partners

Participants will be asked to report the number and type of sexual partners over the last 3 months (both female and male). We will also assess the number of partners participants have had unprotected sex with over the previous 3 months: female (vaginal and anal sex) and male (anal sex).

Contraception use and pregnancy

Participants will be asked to indicate which types of contraception (if any) they are using with current partners. Participants will be asked whether a female partner has been pregnant in the last 3 months, and the outcome of that pregnancy.

STI diagnoses

Participants will be asked to report STI diagnoses over the past 3 months at every follow-up point. We will also assess whether participants have received treatment due to a partner being diagnosed with an STI. In order to assess laboratory diagnoses, all STI diagnoses recorded in sexual health clinic records (in the participating sites) over the study period will be noted at 12 months.

Health-Related Quality of Life

Health-related quality of life (HRQoL) will be assessed using the EQ-5D24,25 which is a 5-item, 3-level questionnaire covering self-care, usual activity, anxiety and depression, pain and mobility. We will also use a newly developed sexual health Quality of Life Scale,26 and compare its performance with the EQ-5D, to assess its suitability for outcome assessment in a sexual health context.

Service use

Use of various sexual health services (e.g. sexual health clinics, general practice, outreach services) over the study period will be assessed.
Engagement with the intervention (patterns of website use)

We will record website usage in order to assess engagement with the intervention (and whether this appears to be related to outcome). The software used will record the number of times each user visits the site, the pages visited, and time spent on each topic section.

Adverse effects

We will record any adverse impacts on sexual health outcomes at 3, 6, 9 and 12 months. Beyond noting any deterioration in outcome measures, participants will also be asked to report whether they have experienced any adverse impacts as a result of the study, recording this in a free text box on each of the follow-up questionnaires. Adverse impacts may also be identified when the research team liaise directly with participants (e.g. follow-up telephone calls to non-responders to questionnaires).

Intervention development costs and trial feasibility indicators

Intervention development costs and recruitment and retention rates will be reported.

5.8.4. Measuring mediators of condom use

While it is important to assess changes in behaviour, it is also important to assess the mediators of behaviour change. This provides information about the mechanisms by which behaviour might have changed. The mediators measured were identified following consultation with experts, a review of the literature, interviews with the target population), and using the theoretical frameworks of the COM-B model and the PRIME theory of motivation.

Condom use errors and problems

To ensure that condom use is ‘correct’, and to assess any impact on condom use skills, we will assess condom use problems at all time-points, using a measure defined by Crosby et al., which assesses the occurrence of 15 condom errors and problems within the last 3 months. The scale was adapted in the light of qualitative fieldwork, to improve relevance and understanding.

Knowledge

Knowledge (of risk of STIs and condom sizes) will be assessed using an 11-item measure, devised based on gaps in men’s knowledge identified in the literature and in interviews with the target population. A number of ‘true or false’ statements regarding misconceptions about condoms and risk will be given (e.g. ‘You would know if you had an STI, without needing a test’; ‘Standard sized condoms are suitable for all men’).

Communication with partners

To assess communication with partners over a 3-month period, we adapted the 6-item Partner Communication Scale. The scale was adapted in the light of qualitative fieldwork, and the recall period was modified from 6 months to 3 months, as all follow-up assessments will be 3 months apart.
Identity

To assess potential links between identity (self-perception) and condom use, we created a 7-item scale, derived from issues relating to condom use identity that had arisen during the fieldwork.

Beliefs about pleasure

Beliefs about pleasure will be assessed using an eight-item scale, adapted from the ‘Effect of sexual experience’ subscale of the Condom Perceived Barriers Scale. The scale was adapted in the light of qualitative fieldwork, to improve relevance and understanding.

Self-efficacy

Self-efficacy will be assessed using a 14-item measure, adapted from the widely validated Brafford and Beck scale. The scale was adapted in the light of qualitative fieldwork, to improve relevance and understanding.

Motivation, intention, and evaluation of condom use

Motivation (want) and intention to use condoms, and evaluation of condom use will be assessed using single-item measures (Robert West, 12th September, 2013, personal communication).

Alcohol and drug use

Alcohol and drug use were found in our fieldwork to be important factors in non-condom use. We therefore included a single item assessing the number of times in the last 3 months participants had unprotected sex when intoxicated.

5.9. Methods to protect against sources of bias

Participants will use the tablet computer without assistance, providing baseline data that will be submitted directly online. A study researcher will be available in the clinic and via telephone, solely to clarify research procedures. Baseline data will be collected prior to randomisation. Once eligibility for the study is established, and baseline data collected, allocation to intervention or control group will be automatically randomly assigned by computer algorithm, and this will not be changeable by participants or researchers. Subsequent outcome data will be collected online using an emailed link to the online outcome questionnaire. Data will be exported and analysed using ID numbers only. Participants will be aware of their allocation to intervention or control group, but the automated data collection procedures protects from researcher bias during data collection.

5.10. Maximising retention

We will follow up participants by email, texts, and by telephone:

1. Automated Emails, with 3 further follow-up emails at weekly intervals
2. 2 text messages – at the same time as the last two emails
3. Contact via telephone a week after the final email
We will offer participants a £10 online shopping voucher for filling in the online questionnaires at 3, 6, and 9 months with a further £20 voucher on completion of the final 12-month follow-up questionnaire. Vouchers will be sent by email.

6. Statistical analysis plan

6.1. Sample size and power calculations

This is a pilot RCT with a primary aim of assessing the success of recruitment and retention, engagement with the intervention, and the acceptability of trial procedures to participants and clinic staff. We will also assess the possible effect size of key outcomes including condom use over the last 3 months, to inform power calculations for a future phase III RCT.

Power calculations were performed based on data from the Sexunzipped online trial. The study is powered to allow estimates of the effect of the intervention on episodes of unprotected vaginal sex over the last 3 months. A sample size of 166 (83 intervention, 83 comparator, randomised 1:1 between experimental and control conditions) is adequate to detect a reduction of 1.35 episodes of unprotected sex with a conventional two sided $\alpha$ of .05 and 90% power ($1-\beta$). Allowing for potential loss to follow-up at 3 months, 122 participants (61 intervention, 61 comparator) is adequate to find a reduction of 1.35 episodes of unprotected sex with a conventional two sided $\alpha$ of .05 and 80% power ($1-\beta$). In addition, this sample size is also sufficient to detect a 1.65 difference in safer sex intention, and a one-point difference in self-efficacy on Likert scales, with a conventional two sided $\alpha$ of .05 and 90% power ($1-\beta$).

6.2. Data Analysis

6.2.1. Analysis of outcomes

Analysis of sexual health outcomes will be based on all participants according to their initial experimental allocation (on an intention-to-treat analysis). Analysis for the primary outcome will use a generalised mixed model, with log link and Poisson/mixed error. The response variable will be the number of episodes of unprotected vaginal sex for each subject. Explanatory variables will be the baseline ($\log_e(x)$) number of episodes of unprotected vaginal sex and the experimental condition. The analysis will include a generalised (random effects) over-dispersion parameter. Comparisons of sexual health between intervention and control groups will include the baseline value of each outcome as subject level explanatory variables, so that analysis is of the difference in endpoint conditional on the within subject baseline measure. For sexual health outcomes measured only at follow-up, we will compare effect sizes between intervention and control groups alone using all available data and describe loss to follow up for each treatment condition. For other outcomes, analyses will be based on generalised linear models with appropriate link functions and error structures. Statistical analyses will be described a priori in a Statistical Analysis Plan, and the principal analyses will be implemented independently by two statisticians.
6.2.2. **Mediation analyses**

We will conduct a prognostic model in order to determine whether change in any of the mediating variables (e.g. beliefs about pleasure, self-efficacy) is associated with any intervention effects. This will help to identify which elements of the website seem to be most influential.

6.3. **Cost effectiveness analysis**

The principal aim of the economic data collection will be to determine the feasibility and validity of collecting cost and outcome data for a cost effectiveness analysis within a phase III trial. We will conduct an initial cost-effectiveness analysis (CEA) of incremental cost per gain in outcome, looking at cost per STI prevented (Chlamydia or Gonorrhoea), comparing intervention participants with controls from the NHS perspective. This will include one way, two way and parametric sensitivity tests.

The aim of the analysis will primarily be to evaluate whether information collected is fit for purpose, and to inform information collection in a future trial. We will examine the feasibility of collecting cost data for intervention and control participants including costs associated with STI tests and treatments, and contract tracing, testing and treatment. Trial subjects may access sexual health services from a range of providers, so information from sexual health clinic notes alone may prove unreliable. We will therefore ask participants about sexual health related health service contacts over the past 12 months as part of the self-reported outcomes. Information collected from sexual health clinic notes will be used to assess the reliability of the self-reported information collected. Personal Social Services Research Unit (PSSRU) reference costs, British National Formulary and other national sources of costing information will be used to calculate unit costs. Costs associated with the maintenance of the intervention website and updating the website will also be included.

STIs prevented will be calculated by taking account of diagnoses recorded from clinical records at 12 month follow-up as well as self-reported episodes for the previous year. We will calculate the cost per episode of Chlamydia or Gonorrhoea prevented for the intervention group versus controls. The National Institute of Health and Care Excellence (NICE) recommends that quality adjusted life years (QALYS) are used as the outcome in cost-effectiveness analysis, to allow for the comparison of results for different cost-effectiveness analyses across disease areas. QALYs are calculated by multiplying health related quality of life (HRQoL) by the amount of time spent in the HRQoL state. The EQ-5D is the questionnaire recommended by NICE to calculate HRQoL; however, it has been recognised though that the EQ-5D may not be suitable for economic evaluations of public health interventions as it may not capture the relevant information on the full psychosocial impact of public health interventions or be sufficiently sensitive for that purpose. We will therefore also collect data on the performance of the Sexual QoL questionnaire to assess its suitability for use in a future large scale RCT.

Acquisition of STI may have cost and QALY impacts that may occur beyond the end of the trial, so it is important this information is accounted for as part of the model. This is commonly achieved by a decision analytical model that has a time horizon beyond the end of the trial and combines
cost and outcome data from a range of published sources in addition to trial information. As a result we will design a decision analytical model that will take account of costs and QALYs for the lifetime of the service users. The values in the decision analytical model will come from a comprehensive review of the literature including the efficacy of condoms, research to increase condom use and the incidence and prevalence of STIs. The quality of each of the type of evidence and relevance to the UK context will be assessed to determine the best coefficients to use in the cost-effectiveness model. We will also aim to determine utility values for the long term QALY outcomes associated with STIs. The final model will compare the incremental cost per QALY gained and cost per STI prevented of the internet based intervention versus the control group. It will be subject to one way, two way and probabilistic sensitivity analyses (PSA) and a cost effectiveness acceptability curve calculate to determine the probability that the internet based intervention is cost effective for a range of values of willingness to pay for an outcome gained.

7. Ethical issues

7.1. Ethics committee approval

This study was approved by the City and East NHS Research Ethics Committee (Study reference number 13 LO 1801).

7.2. Potential ethical issues

This project aims to encourage behaviour change to reduce morbidity and the social and emotional costs of STI acquisition, with the aim of benefiting trial participants as well as wider society.

There is a risk that the study may unintentionally exacerbate the stigma of STI and risky behaviour for participants. We strive to be non-judgemental about choices of lifestyle or behaviour, respecting others’ autonomy. It could be that participants’ partners or others see the intervention website, texts to participants’ mobile phones or email messages. Study information makes clear to participants the nature of study-related communications and possible risks. However, there is a danger that this may be accessed by others and that this leads to embarrassment or relationship difficulties in some way. A component of the intervention will focus on communication with partners, so it is hoped that the intervention will improve the quality of relationships rather than cause harm.

Participants will receive detailed information about the study including risks and benefits while being led through the consent process on the trial software. Participants will be offered the opportunity to ask the researcher any further questions.

7.3. Informed consent form and information sheet

Informed consent will be obtained using a standardised Participant Information Sheet (PIS) and consent form (both integrated into the trial software), which have been approved by the London – City and East ethics committee and local NHS Research and Development offices.
All participants included in the trial will be asked for their consent to take part and for their contact details to be used to communicate with them (e.g. for follow-up questionnaires, and reminders to use the website), and for data obtained as a result of their use of the NHS services (i.e. medical records) to be used for research purposes. Users will not be able to register for the study unless they consent to all statements. We will ensure that all research procedures meet the highest standards for data protection and confidentiality, storing data on an encrypted server. We will give participants the contact details for support organisations in case they are needed, and follow protocols to ensure the safety and wellbeing of participants under the age of 18 who may be at risk of harm.

8. Monitoring

The trial is overseen by a Trial Management Group (TMG) that will meet at least quarterly. Their role is to advise on all issues to do with the design and conduct of the trial.

The trial being conducted in association with PRIMENT clinical trials unit, which is a UK Clinical Research Collaboration registered clinical trials unit, and has experience of working on e-health trials. Representatives from PRIMENT are also members of the TMG (including a statistician, a health economist, and an expert in sexual health trials).

The trial is also monitored by an independent Trial Steering committee (TSC) which meets twice a year. The role of the TSC is monitoring adherence to protocol and ensuring that patient interests are prioritised above the interests of the research.

The trial has been judged to represent low risk to participants. However, adverse events will be collected and assessed according to the principles of Good Clinical Practice by the chief investigator assisted by the study statistician.

8.1. Interim analyses and stopping rules

The TMG, including the trial statistician, will meet quarterly to monitor the conduct and progress of the trial. The chief investigator and the trial statistician will monitor data blind to treatment allocation to identify any unexpected deterioration in outcomes or reported adverse effects.

9. Indemnities

University College London is the research sponsor, and indemnity insurance certificates have been obtained from them.

10. Publication plan

The following papers will be prepared and submitted for publication in peer reviewed journals

- Description of the development process of the MenSS intervention website
- Description of the content of the MenSS intervention website
- Main findings of the pilot trial
- Findings of a qualitative process evaluation of trial procedures
- Exploration of the relationship between mediators of condom use behaviour and outcome measures

11. Funder

This trial is funded by a Health Technology Assessment grant from the National Institute for Health Research. Ref. 10/131/01  
http://www.nets.nihr.ac.uk/projects/hta/1013101

12. Timeline

Study Start Date
April 2014

Expected end date
August 2015

Expected submission date
September 2015

13. Sponsor

University College London, UK

14. Clinical trial registration:

ISRCTN18649610 (http://www.controlled-trials.com/ISRCTN18649610)
Reference List

(1) NICE. One to one interventions to reduce the transmission of sexually transmitted infections (STIs) including HIV, and to reduce the rate of under 18 conceptions, especially among vulnerable and at risk groups. London: National Institute for Health and Clinical Excellence; 2007.


(14) National Institute for Health and Clinical Excellence. One to one interventions to reduce the transmission of sexually transmitted infections (STIs) including HIV, and to reduce the rate of under 18 conceptions, especially among vulnerable and at risk groups. 2007. 4-7-2013.


(35) Curtis L. Unit Costs of Health and Social Care. 2013. Personal Social Services Research Unit. Ref Type: Online Source

